Bristol Myers Squibb Company
NEWS
A Minnesota woman, Denise Miley, is suing Bristol-Myers Squibb and Otsuka Pharmaeutical, alleging that their Abilify (aripiprazole) for depression and anxiety, caused a gambling impulse. Her suit isn’t the only one.
Two of Amgen’s executive vice presidents are leaving the company.
For the first time, Merck’s Keytruda beat out Bristol-Myers Squibb’s Opdivo in sales.
Bristol-Myers Squibb reported a strong second quarter, with total revenues of $5.7 billion, up 11 percent from the same quarter in 2017, when it reported $5.144 billion. Sales were driven by Eliquis (apixaban) and Opdivo (nivolumab).
This morning IFM Tre, a subsidiary of IFM Therapeutics, launched with $31 million in the bank and a focus on developing a suite of different NLRP3 antagonists.
Roche’s Tecentriq, in combination with chemotherapy, hit its co-primary endpoint of progression-free survival in a Phase III trial for non-small cell lung cancer patients. But, the Swiss pharma giant said the combination has so far failed to achieve statistical significance in overall survival, a co-primary trial endpoint.
Shares of Advaxis are skyrocketing this morning after the company announced the U.S. Food and Drug Administration lifted the clinical hold on its Investigational New Drug Application for a Phase I/II cancer study.
Changes continue coming to Vivek Ramaswamy’s Roivant Sciences following a June shakeup that saw a 10 percent cut in employment and the restructuring of its business operations.
On May 29, the FDA cleared T2 Biosystems’ T2Bacteria Panel for diagnosis of sepsis. In that sepsis is the third-leading cause of death in the U.S., this emphasizes the importance of work in this area.
JOBS
IN THE PRESS